Statins

Why This Matters

Statins are among the most extensively studied medications in the history of medicine and remain the foundation of lipid-lowering therapy. Although they are commonly described as "cholesterol-lowering drugs," this description is incomplete. Their greatest clinical benefit results not simply from reducing cholesterol synthesis, but from increasing the liver's ability to remove ApoB-containing lipoproteins from the circulation.

What Are Statins?

Statins are competitive inhibitors of HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol synthesis.

By reducing hepatic cholesterol synthesis, statins lower intracellular cholesterol concentrations within hepatocytes. This activates normal feedback mechanisms that increase LDL receptor expression, allowing the liver to remove more ApoB-containing lipoproteins from the bloodstream.

The reduction in circulating ApoB particle number is the principal mechanism by which statins lower cardiovascular risk.

How Statins Work

The immediate effect of statins is inhibition of hepatic cholesterol synthesis.

As intracellular cholesterol declines, sterol regulatory element-binding proteins (SREBPs) become activated, increasing the expression of LDL receptors on hepatocytes. More LDL receptors result in more rapid removal of LDL, IDL, remnant lipoproteins, and other ApoB-containing particles from the circulation.

Clinical Benefits

Numerous randomized clinical trials have demonstrated that statins reduce myocardial infarction, ischemic stroke, coronary revascularization, and cardiovascular mortality.

The magnitude of benefit generally parallels the degree of ApoB and LDL cholesterol reduction. Patients at highest cardiovascular risk derive the greatest absolute benefit because they have the greatest potential reduction in lifetime exposure to ApoB-containing lipoproteins.

The Cholesterol Treatment Trialists' Collaboration, a meta-analysis pooling more than 20 randomized statin trials, found a remarkably consistent dose-response relationship: each 39 mg/dL (1 mmol/L) reduction in LDL cholesterol produces roughly a 21 to 22 percent relative reduction in major cardiovascular events, regardless of which statin is used or what the starting LDL cholesterol level was. In practical terms, moderate-intensity statins lower LDL cholesterol by about 30 to 49 percent and high-intensity statins by 50 percent or more, and the corresponding cardiovascular benefit scales with that reduction. This dose-response relationship, replicated across dozens of trials and hundreds of thousands of patients, is among the best-established findings in cardiovascular medicine.

Adverse Effects

Most patients tolerate statins well.

The most commonly reported adverse effects involve skeletal muscle symptoms ranging from mild myalgias to, rarely, rhabdomyolysis. Mild elevations in liver enzymes may occur but serious hepatotoxicity is uncommon.

Statins are also associated with a small increase in the risk of new-onset diabetes mellitus, particularly in individuals with preexisting insulin resistance. In patients at elevated cardiovascular risk, the reduction in cardiovascular events generally outweighs this modest increase in diabetes risk — though the finding is a genuine reason patients with strong insulin-resistance risk factors deserve the fuller metabolic workup this book's main chapters describe, not a reason to avoid the drug reflexively.

Not All Statins Are Identical

Statins differ in potency, pharmacokinetics, metabolism, and lipid-lowering efficacy.

High-intensity statins generally achieve the greatest reductions in LDL cholesterol and ApoB. Lipophilic and hydrophilic statins also differ in tissue distribution, although the clinical significance of these differences remains uncertain for most patients.

Therapy should be individualized according to cardiovascular risk, treatment goals, medication tolerance, and patient preference.

Clinical Relevance

Statins remain the first-line pharmacologic therapy for lowering ApoB-containing lipoproteins.

When LDL cholesterol goals are not achieved with maximally tolerated statin therapy, additional agents such as ezetimibe, PCSK9 inhibitors, bempedoic acid, or inclisiran may be added to further reduce ApoB exposure. The guiding principle remains the same: reducing the number of circulating ApoB-containing particles lowers cumulative cardiovascular risk.

Clinical Pearls

• Statins inhibit HMG-CoA reductase.
• Their greatest clinical benefit results from increasing hepatic LDL receptor expression.
• Statins reduce both LDL cholesterol and ApoB concentrations.
• Cardiovascular benefit is proportional to the reduction in lifetime ApoB exposure.
• Statins remain the foundation of lipid-lowering therapy.

Common Misconceptions

Misconception: Statins work simply by reducing cholesterol production.

Reality: Their greatest clinical benefit results from increasing hepatic LDL receptor-mediated clearance of ApoB-containing lipoproteins.

Misconception: Statins eliminate cardiovascular risk.

Reality: Statins substantially reduce risk but do not eliminate it. Residual risk may persist because of elevated Lp(a), remnant lipoproteins, diabetes, hypertension, smoking, inflammation, or other factors.

Misconception: Muscle symptoms occur in most patients taking statins.

Reality: Most patients tolerate statins well, and serious muscle injury is uncommon.

Clinical Bottom Line

Statins reduce cardiovascular risk primarily by increasing hepatic LDL receptor activity and lowering the number of circulating ApoB-containing lipoproteins. Their effectiveness, extensive evidence base, and favorable benefit-risk profile have made them the cornerstone of modern preventive cardiology.